Welcome to our dedicated page for BIOPLUS ACQUISITION news (Ticker: BIOSW), a resource for investors and traders seeking the latest updates and insights on BIOPLUS ACQUISITION stock.
BioPlus Acquisition Corp. (BIOSW) provides investors with authoritative updates on corporate developments within the healthcare sector. This page aggregates official announcements regarding the company's ongoing liquidation process and related shareholder actions.
Access verified information about BIOSW's dissolution timeline, including redemption procedures for public shares and warrant status updates. Our curated news collection ensures transparent tracking of regulatory filings and material corporate events.
Key updates cover dissolution milestones, capital distribution details, and compliance with organizational charters. Bookmark this page for direct access to BIOSW's press releases and SEC disclosures as the liquidation process progresses.
BioPlus Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 20 million units at $10.00 each. The units will begin trading on Nasdaq on December 3, 2021, under the ticker symbol BIOSU. Each unit comprises one Class A share and one-half of a redeemable warrant, which allows the purchase of one Class A share at $11.50. The securities will eventually trade separately under BIOS for shares and BIOSW for warrants. The company focuses on the life sciences sector for its business combinations.
BioPlus Acquisition Corp. announced the pricing of its upsized initial public offering (IPO) of 20 million units at $10.00 per unit, set to trade on Nasdaq under the symbol BIOSU starting December 3, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, with each whole warrant allowing the purchase of one share at $11.50. The company aims to pursue mergers or acquisitions primarily within the life sciences sector, with Cantor Fitzgerald & Co. as the sole book-running manager for this offering.
